Literature DB >> 35110735

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.

J Joseph Melenhorst1,2,3,4,5, Gregory M Chen6, Meng Wang7,8,9, David L Porter9,10, Changya Chen11,12, McKensie A Collins7,8,9,13, Peng Gao11,12, Shovik Bandyopadhyay13, Hongxing Sun7,8,9, Ziran Zhao7,8,9, Stefan Lundh7,8,9, Iulian Pruteanu-Malinici14, Christopher L Nobles15, Sayantan Maji7,8,9, Noelle V Frey9, Saar I Gill9, Lifeng Tian7,9, Irina Kulikovskaya7,8,9, Minnal Gupta7,8,9, David E Ambrose7,8,9, Megan M Davis7,8,9, Joseph A Fraietta7,8,9,15, Jennifer L Brogdon14, Regina M Young7,8,9, Anne Chew7,8,9, Bruce L Levine7,8,9, Donald L Siegel7,8,16, Cécile Alanio17,18,19, E John Wherry17,18,19, Frederic D Bushman15, Simon F Lacey7,8,9, Kai Tan20,21,22,23,24, Carl H June25,26,27,28,29.   

Abstract

The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers1-7. However, little is known about the long-term potential and clonal stability of the infused cells. Here we studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia1-4 who achieved a complete remission in 2010. CAR T cells remained detectable more than ten years after infusion, with sustained remission in both patients. Notably, a highly activated CD4+ population emerged in both patients, dominating the CAR T cell population at the later time points. This transition was reflected in the stabilization of the clonal make-up of CAR T cells with a repertoire dominated by a small number of clones. Single-cell profiling demonstrated that these long-persisting CD4+ CAR T cells exhibited cytotoxic characteristics along with ongoing functional activation and proliferation. In addition, longitudinal profiling revealed a population of gamma delta CAR T cells that prominently expanded in one patient concomitant with CD8+ CAR T cells during the initial response phase. Our identification and characterization of these unexpected CAR T cell populations provide novel insight into the CAR T cell characteristics associated with anti-cancer response and long-term remission in leukaemia.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35110735      PMCID: PMC9166916          DOI: 10.1038/s41586-021-04390-6

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  1 in total

1.  Analysis of Signaling Networks at the Single-Cell Level Using Mass Cytometry.

Authors:  Shovik Bandyopadhyay; Daniel A C Fisher; Olga Malkova; Stephen T Oh
Journal:  Methods Mol Biol       Date:  2017
  1 in total
  52 in total

Review 1.  Tumour immunotherapy: lessons from predator-prey theory.

Authors:  Phineas T Hamilton; Bradley R Anholt; Brad H Nelson
Journal:  Nat Rev Immunol       Date:  2022-05-05       Impact factor: 53.106

2.  Cytotoxic CD4+ CAR T cells implicated in long-term leukaemia remission.

Authors:  Alexandra Flemming
Journal:  Nat Rev Immunol       Date:  2022-03       Impact factor: 53.106

Review 3.  Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Authors:  Pei-Hua Lu; Kai-Yan Liu; Xing-Yu Cao; Jing-Jing Li
Journal:  Int J Hematol       Date:  2022-06-23       Impact factor: 2.319

Review 4.  B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?

Authors:  Gregory M Chen; Jan Joseph Melenhorst; Kai Tan
Journal:  Sci Transl Med       Date:  2022-06-22       Impact factor: 19.319

Review 5.  Therapeutic Strategies for Immune Transformation in Parkinson's Disease.

Authors:  Maamoon Saleh; Milica Markovic; Katherine E Olson; Howard E Gendelman; R Lee Mosley
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

6.  Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.

Authors:  Yong Gu Lee; Puneeth Guruprasad; Guido Ghilardi; Raymone Pajarillo; Christopher Tor Sauter; Ruchi Patel; Hatcher J Ballard; Seok Jae Hong; Inkook Chun; Nicholas Yang; Kimberly V Amelsberg; Katherine D Cummins; Jakub Svoboda; Saar Gill; Elise A Chong; Khrystyna North; Sarah E Church; Joseph A Fraietta; Wan-Jung Chang; Simon F Lacey; Xueqing Maggie Lu; Yunlin Zhang; Kanupriya Whig; David C Schultz; Sara Cherry; James Gerson; Stephen J Schuster; Patrizia Porazzi; Marco Ruella
Journal:  Cancer Discov       Date:  2022-10-05       Impact factor: 38.272

Review 7.  Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.

Authors:  Baixin Ye; Yongxian Hu; Mingming Zhang; He Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

Review 8.  Progress on CAR-T cell therapy for hematological malignancies.

Authors:  Kejia Hu; Yue Huang; Yongxian Hu; He Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

9.  Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.

Authors:  Nicholas J Haradhvala; Mark B Leick; Katie Maurer; Satyen H Gohil; Rebecca C Larson; Ning Yao; Kathleen M E Gallagher; Katelin Katsis; Matthew J Frigault; Jackson Southard; Shuqiang Li; Michael C Kann; Harrison Silva; Max Jan; Kahn Rhrissorrakrai; Filippo Utro; Chaya Levovitz; Raquel A Jacobs; Kara Slowik; Brian P Danysh; Kenneth J Livak; Laxmi Parida; Judith Ferry; Caron Jacobson; Catherine J Wu; Gad Getz; Marcela V Maus
Journal:  Nat Med       Date:  2022-09-12       Impact factor: 87.241

10.  Last-resort cancer therapy holds back disease for more than a decade.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2022-02       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.